EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Tinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma

Shrunal Mane, Vincent Walter, Marie-Therese Abdou, Stefan Diem, Nina Wyss, Kira-Lee Koster, Lenka Besse, Dagmar Hess, Yannis Metaxas, Marie-Claire Flynn, Stefanie Aeppli, Taemer El Saadany und 4 weitere

Cancer Immunology, Immunotherapy · 05.11.2026 · 75 (11)

DOI: 10.1007/s00262-026-04608-4 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 05.11.2026. Verfasst von Shrunal Mane und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital, Liebermeisterstraße 20, 72076, Tübingen, Germany. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Combined Chemotherapy Protocols, Nivolumab, Immunity, Humoral. Die Arbeit nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mundipharma Research Ltd, Knoa Pharma LLC, Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ENIgMA is a phase IB trial (NCT03903458; SNCTP000003243) evaluating the safety and preliminary activity of the first-in-class alkylating deacetylase inhibitor tinostamustine in combination with nivolumab (3 mg/kg) in patients with predominantly immune checkpoint inhibitor (ICI)-resistant, advanced melanoma. We conducted this longitudinal immune monitoring study in 15 of the 17 enrolled patients to characterize systemic immunologic changes associated with an immunomodulatory dose of tinostamustine. We have previously demonstrated that combination of tinostamustine with nivolumab was able to induce disease stabilization in 54% and confirmed partial responses in 23% of evaluable patients. Peripheral blood samples collected longitudinally during treatment were analysed by flow cytometry, serum antigen-specific IgG enzyme-linked immunosorbent assay (ELISA), and intracellular cytokine staining following ex vivo peptide stimulation. Longitudinal flow cytometric analyses demonstrated dynamic changes in peripheral immune subsets, including T cells, natural killer (NK) cells and monocytes, suggesting ongoing immune engagement during tinostamustine–nivolumab therapy. In progressors, elevated baseline lactate dehydrogenase (LDH) levels significantly and inversely correlated with circulating T cell frequencies, indicating distinct immune profiles associated with poor clinical outcome. Antigen-specific adaptive immune responses were detectable despite extensive prior treatment and high tumour burden. CD4+ T cell responses, particularly TNFα-associated responses directed against melanoma-associated antigens, represented the dominant cellular immune activation pattern. Additionally, treatment related increases in melanoma-associated antigen-specific IgG responses were also observed in several patients. Collectively, these findings demonstrate that immunomodulatory doses of tinostamustine in combination with nivolumab are linked with preserved adaptive immune competence and detectable cellular and humoral immune activation in heavily pre-treated patients with advanced melanoma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaAntineoplastic Combined Chemotherapy ProtocolsNivolumabImmunity, HumoralImmunity, CellularHumansFemaleMaleMiddle AgedAgedAdultKiller Cells, Natural

Stichwörter der Autor:innen

Heavily pre-treated patientsHistone deacetylase (HDAC) inhibitorsMelanomaNivolumabTinostamustine

Substanzen

Nivolumab

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital, Liebermeisterstraße 20, 72076, Tübingen, Germany.
  • Department of Dermatology, Institute of Immunobiology, St. Gallen, Switzerland.
  • Department of Medical Oncology and Hematology, Cantonal Hospital, St. Gallen, Switzerland.
  • Department of Internal Medicine, Regional Hospital, Grabs, Switzerland.
  • Department of Dermatology, Cantonal Hospital, St. Gallen, Switzerland.
  • Department of Oncology and Hematology, Laboratory of Experimental Oncology, Cantonal Hospital, St. Gallen, Switzerland.

Förderung

  • Mundipharma Research Ltd
  • Knoa Pharma LLC
  • Bristol-Myers Squibb
  • Universitätsklinikum Tübingen

Zitieren

APA

Mane, S., Walter, V., Abdou, M. T., Diem, S., Wyss, N., Koster, K. L., Besse, L., Hess, D., Metaxas, Y., Flynn, M. C., Aeppli, S., El Saadany, T., Hiendlmeyer, E., von Moos, R., Joerger, M., & Flatz, L. (2026). Tinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma. Cancer Immunology, Immunotherapy, 75(11). https://doi.org/10.1007/s00262-026-04608-4

Vancouver

Mane S, Walter V, Abdou MT, Diem S, Wyss N, Koster KL, et al. Tinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma. Cancer Immunology, Immunotherapy. 2026;75(11). doi:10.1007/s00262-026-04608-4

BibTeX
@article{Mane2026,
  author = {Mane, Shrunal and Walter, Vincent and Abdou, Marie-Therese and Diem, Stefan and Wyss, Nina and Koster, Kira-Lee and Besse, Lenka and Hess, Dagmar and Metaxas, Yannis and Flynn, Marie-Claire and Aeppli, Stefanie and El Saadany, Taemer and Hiendlmeyer, Elke and von Moos, Roger and Joerger, Markus and Flatz, Lukas},
  title = {Tinostamustine–nivolumab therapy is associated with antigen-specific cellular and humoral immune responses in heavily pre-treated patients with advanced melanoma},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  volume = {75},
  number = {11},
  doi = {10.1007/s00262-026-04608-4}
}
Kostenlos starten →